Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

EXAMPLE 121fert-Butyl 3-(quinoxalin-6-yl)benzylcarbamate6-Bromoquinoxaline (500 mg, 2.39 mmol), 3-(aminomethyl)phenylboronic acid hydrochloride (445 mg, 2.39 mmol), potassium phosphate (1000 mg, 4.78 mmol), water (3 mL), DME (13 mL) and Pd(PPh3)4 (277 mg, 0.24 mmol) were combined in a sealed tube and heated under microwave irradiation to 1400C for 1 h. Di-tert-butyl dicarbonate (545 mg, 2.50 mmol) was then added and the reaction mixture stirred at room temperature for 18 h. The organic layer was concentrated to dryness and purified by chromatography (SiO2, 20-100% EtOAc in petroleum ether) to give a yellow gum (232 mg). A sample (30 mg) was further purified by preparative HPLC to give the title compound (21.6 mg) as a clear solid. deltaH (CDCl3) 8.88 (IH, d, J 1.85 Hz), 8.85 (IH, d, J 1.86 Hz), 8.31 (IH, d, J 2.05 Hz), 8.18 (IH, d, J 8.73 Hz), 8.05 (IH, dd, J 8.74, 2.08 Hz), 7.67 (2H, d, J6.92 Hz), 7.49 (IH, t, J7.84 Hz), 7.37 (IH, d, J7.61 Hz), 4.93 (IH, s), 4.44 (2H, d, J5.95 Hz), 1.48 (9H, s). LCMS (ES+) 336 (M+H)+, RT 3.58 minutes {Method 2).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

55687-02-0, In a 10 ml seal tube, methyl (4S,7S)-6,10-dioxo-4-(5-(4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)- 1 H-imidazol-2-yl)octahydro- 1 H-pyridazino [ 1 ,2- a][l,2]diazepin-7-ylcarbamate (240 mg, 459 muiotaetaomicron?) (Intermediate 3), 6-bromo-2- chloroquinoxaline (112 mg, 459 muiotaetaomicron?) and Cs2C03 (299 mg, 917 muiotaetaomicron?) were combined with 1,4-dioxane (3.00 ml) and water (0.5 ml) to give a light brown solution. It was degased for 10 min and tetrakis(triphenylphosphine)palladium (0) (53.0 mg, 45.9 muiotaetaomicron?) was added. The reaction mixture was heated at 80 C for 16 h. It was diluted with EtOAc (6 ml) andconcentrated in vacuo. The residue was purified on a silica gel column (CH2C12, 2%, 3%, 5%, 8% and 10% MeOH/CH2Cl2 ) to afford methyl (4S,7S)-4-(5-(4-(6-bromoquinoxalin-2- yl)phenyl)- 1 H-imidazol-2-yl)-6, 10-dioxooctahydro- 1 H-pyridazino [ 1 ,2-a] [ 1 ,2]diazepin-7- ylcarbamate as a red solid (240 mg, 86.6%). ESI-LRMS m/e calcd for C28H26BrN704 [M+] 604, found 605 [M+H+].

As the paragraph descriping shows that 55687-02-0 is playing an increasingly important role.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; BRINKMAN, John A.; LI, Hongju; SARABU, Ramakanth; SO, Sung-Sau; WO2013/53657; (2013); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

49679-45-0, Method A: a solution of compound 3 (1.11 g, 4.70 mmol), 3- aminophenol (622 mg, 5.70 mmol) and p-TSA, as a catalyst, in absolute ethanol (40 mL) was refluxed for 110 h. Ethanol was then evaporated under reduced pressure, and the resulting residue was purified by silica column chromatography using cyclohexane with ethyl acetate gradient (0e50%) as eluent to give the desired compound 4a (1.0 g, 69%) as a red powder. Mp 233.3 C. 1 H NMR (300 MHz, DMSO-d6) d 10.08 (bs, 1H, NH), 9.52 (bs, 1H, OH), 7.99 (dd, 1H, J 8.4, 0.6 Hz), 7.85e7.75 (m, 2H), 7.61e7.54 (m, 2H), 7.24e7.14 (m, 2H), 6.51 (dd, 1H, J 7.4, 2.4, 1.5 Hz), 4.48 (q, 2H, J 7.2 Hz, CH2), 1.41 (t, 3H, J 7.2 Hz, CH3). 13C NMR (75 MHz, DMSO-d6) d 166.1, 158.3, 148.8, 142.4, 140.7, 136.0, 133.4, 132.7, 130.0 (2 C), 126.7, 126.6, 111.1, 110.6, 107.3, 62.8, 14.5.

The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Oyallon, Bruno; Brachet-Botineau, Marie; Loge, Cedric; Bonnet, Pascal; Souab, Mohamed; Robert, Thomas; Ruchaud, Sandrine; Bach, Stephane; Berthelot, Pascal; Gouilleux, Fabrice; Viaud-Massuard, Marie-Claude; Denevault-Sabourin, Caroline; European Journal of Medicinal Chemistry; vol. 154; (2018); p. 101 – 109;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

49679-45-0, Ethyl 3-chloroquinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To ethyl 3-chloroquinoxaline-2-carboxylate 1 (1 g, 4.22 mmol),appropriate acetylene derivative (3.33 mmol, 1.5 eq.) in ethanol(15 mL) was added in a two-necked flask containing triethylamine(1.4 mL, 10 mmol), Pd/C (45 mg, 0.42 mmol), triphenylphosphine(110 mg, 0.42 mmol), and CuI (50 mg, 0.26 mmol). The reaction mixture was stirred at 60 C for 5 h. After cooling, the mixture wasfiltered with celite and the filtrate diluted with dichloromethane,washed with H2O (3 x 40 mL) and dried over MgSO4. After evaporation,the crude product was purified by silica gel chromatography(CH2Cl2).

49679-45-0, The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Hajri, Majdi; Esteve, Marie-Anne; Khoumeri, Omar; Abderrahim, Raoudha; Terme, Thierry; Montana, Marc; Vanelle, Patrice; European Journal of Medicinal Chemistry; vol. 124; (2016); p. 959 – 966;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

55687-02-0, To a stirred suspension of (2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1-{[2 (trimethylsilyl) ethoxy]methyl}- 1 H-imidazol-5-yl)boronic acid (150 mg, 0.26 mmol), obtained from Preparation 13b, in 1 ,2-dimethoxyethane (1 mL), was added 6-bromo-2-chloroquinoxaline (62 mg, 0.26 mmol), obtained from Preparation 30,Pd(dppf)CI2.DCM (13 mg, 0.05mmol) and 2M Na2CO3 (aq) (0.38 mL, 0.77 mmol). The mixture was degassed, then put under nitrogen three times and then stirred at 300C for 3 hours. The resulting dark brown mixture was partitioned between ethyl acetate (5 mL) and water (5 mL). The organic phases were extracted and the aqueous phase was washed with more EtOAc (5 mL). The organic phases were combined, dried (Na2SO4), filtered and concentrated in vacuo. The resulting crude material was purified by column chromatography (dry loaded redisep (4 g), 20 to 80 % ethyl acetate, heptane) to give 98 mg of the title compound as a orange foam.1H-NMR (400 MHz, MeOD): delta= 9.28 (1 H, d), 8.22 (1 H, d), 7.95 (3H, m), 6.70 (1 H, m), 5.95 (1 H, dd), 5.16(1 H, m), 3.75-3.52 (4H, m), 2.42 (1 H, m), 2.24-1.91 (3H, m), 1.46-1.21 (9H, m), 0.86 (2H, m), -0.17 (9H, d).LCMS (run time = 6 min): Rt = 4.38 min; m/z 574; 576 [M+H]+

As the paragraph descriping shows that 55687-02-0 is playing an increasingly important role.

Reference£º
Patent; PFIZER LIMITED; MILBANK, Jared Bruce John; PRYDE, David Cameron; TRAN, Thien Duc; WO2011/4276; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.148231-12-3,5,8-Dibromoquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of 5,8-dibromoquinoxaline (3) (287 mg, 1.0 mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (9.5 mg, 0.05 mmol) and PPh3 (26 mg, 0.1 mmol) in triethylamine/tetrahydrofuran 1:1 (20 mL) was stirred and heating until 70 148231-12-3, The synthetic route of 148231-12-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Aguiar, Leonardo de O.; Junior, Adalberto S.L.; Bechtold, Ivan H.; Curcio, Sergio Fernando; Cazati, Thiago; Alves, Tiago V.; Vieira, Andre Alexandre; Journal of Molecular Liquids; vol. 296; (2019);,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, vi) [(1R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)-cyclohexyl]-quinoxalin-6-yl- amine: A solution of (1 R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)- cyclohexylamine (34 mg), 6-bromoquinoxaline (23 mg), NaOt-Bu (13 mg), Pd2(dba)3 ‘ CHCI3 (1.9 mg) and BINAP (3.5 mg) in de-gassed toluene (2 ml) was stirred under Ar atmosphere for 1.5 h at 100. The mixture was distributed between cold 1 M Na2CO3 and EtOAc, the phases EPO separated, the aqueous phase ectracted with EtOAc, the combined organic phases dried over Na2SO4 and evaporated. Chromatography afforded 38 mf of the desired product (83%).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GmbH; WO2006/114260; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

148231-12-3, 5,8-Dibromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 5,8-dibromoquinoxaline (3) (287 mg, 1.0 mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (9.5 mg, 0.05 mmol) and PPh3 (26 mg, 0.1 mmol) in triethylamine/tetrahydrofuran 1:1 (20 mL) was stirred and heating until 70 148231-12-3, The synthetic route of 148231-12-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Aguiar, Leonardo de O.; Junior, Adalberto S.L.; Bechtold, Ivan H.; Curcio, Sergio Fernando; Cazati, Thiago; Alves, Tiago V.; Vieira, Andre Alexandre; Journal of Molecular Liquids; vol. 296; (2019);,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To an oven-dried one-arm round bottom flask were added 6-bromoquinoxaline (10b) (216 mg,1.00 mmol), Pd(PPh3)2Cl2 (14.3 mg, 20.0 mumol), CuI (19.5 mg, 100 mumol) and anhydrous THF(2 mL) under argon atmosphere. The solution was bubbled with argon gas for 7 min to remove the dissolved gases. Then, trimethylsilylethyne (537 muL, 3.80 mmol) and Et3N (893 muL, 6.41mmol) were added sequentially, and the reaction mixture was stirred at rt for 14 h. Upon completion of the reaction, the reaction mixture was diluted with EtOAc (10 mL) and washed with water (2 ¡Á 7 mL) and brine (7 mL). The organic layer was dried over anhydrous MgSO4,filtered, and concentrated by rotary evaporation. Purification by column chromatography (10:1hexanes/EtOAc) yielded 11b (110 mg, 49%) as a brown solid., 50998-17-9

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Jeong, Yunkyung; Lee, Jooyeon; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry; vol. 24; 9; (2016); p. 2114 – 2124;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A mixture of N- (4- (methylsulfonyl) benzyl) -3, 4-dihydro-2H- 1 , 4-benzoxazine-7-carboxamide (0.028 g, 0.08 mmol) , 6- bromoquinoxaline (33 mg, 0.160 mmol), RuPhos Pd Gl (5.83 mg, 8.00 mumol), RuPhos (3.73 mg, 8.00 muetaalphaomicron) , NaOtBu (0.023 g, 0.240 mmol) and D E (1 mL) was heated at 130 C for 2 h under (3825) microwave irradiation. The reaction mixture was diluted with AcOEt (3 mL) and quenched with H20 (1 mL) , and stirred for 2 min. The organic layer was separated and then the aqueous layer was extracted with EtOAc (2 mL) . The combined organic layer was evaporated by blowing away with the air at 60 C. The residue was purified by preparative HPLC (Actus Triart C18, eluted with MeCN/10 itiM NH4HCO3 aq. 5:95?100:0). Pure fractions were combined and concentrated by blowing away with the air at 60C to afford the title compound (18.3 mg, 0.0368 mmol, 48%)., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; YAMAMOTO, Satoshi; SHIRAI, Junya; KONO, Mitsunori; SHIOKAWA, Zenyu; YUKAWA, Tomoya; IMADA, Takashi; NEGORO, Nobuyuki; ODA, Tsuneo; SASAKI, Satoshi; NARA, Yoshi; SUZUKI, Shinkichi; SATO, Ayumu; ISHII, Naoki; SHIBUYA, Akito; NAKAGAWA, Yasuo; COLE, Derek; GIBSON, Tony; IVETAC, Anthony; SWANN, Steve; TYHONAS, John; (472 pag.)WO2018/30550; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider